$ALKS

Gaffin David Joseph sold $99K of ALKS

Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares of Alkermes plc. (ALKS) at $48.58 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gaffin David Joseph
Published Aug 3, 2026, 11:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings; it does not provide new company performance or outlook data.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates make it low-impact.

03

What to watch

The filing does not include any accompanying corporate event (guidance, contract, trial, or restructuring), so traders should avoid over-interpreting it as a fundamental signal.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-03 (same day as the sale)

Background

The article is a SEC Form 4 insider transaction for Alkermes plc, reported by an EVP and executed as an open-market sale under a 10b5-1 plan.

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes disclosed an EVP open-market sale of 2,034 shares at $48.58 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

Form 4 shows a planned open-market transaction by an officer, not a new operational or financial disclosure.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated.

None indicated.

Counterpoint

Because it is explicitly under a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Alkermes plc

    Subject of the Form 4 insider transaction disclosure.

  • Gaffin David Joseph

    EVP, CLO at Alkermes, reported an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

$ALKSMedAI 8/10

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.